☆ 4.8 Review

Pancreatic adverse events of immune checkpoint inhibitors therapy for solid cancer patients: a systematic review and meta-analysis

FRONTIERS IN IMMUNOLOGY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non-Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01)

Zhijie Wang et al.

Summary: The CHOICE-01 study investigated the efficacy and safety of toripalimab in combination with chemotherapy as a first-line treatment for advanced non-small-cell lung cancer (NSCLC). The study found that toripalimab plus chemotherapy significantly improved progression-free survival (PFS) and overall survival (OS) compared to placebo.

JOURNAL OF CLINICAL ONCOLOGY (2023)

添加到收藏夹

Article Oncology

Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134

Michael B. Atkins et al.

Summary: Combination programmed cell death protein 1/cytotoxic T-cell lymphocyte-4-blockade and dual BRAF/MEK inhibition have shown significant clinical benefit in patients with BRAFV600-mutant metastatic melanoma. This study aimed to determine the best initial treatment or treatment sequence in this population.

JOURNAL OF CLINICAL ONCOLOGY (2023)

添加到收藏夹

Article Oncology

NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC

Gilberto de Castro Jr et al.

Summary: In the NEPTUNE study, first-line durvalumab plus tremelimumab did not show significant improvement in overall survival compared to chemotherapy in patients with metastatic NSCLC.

JOURNAL OF THORACIC ONCOLOGY (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma

Ann-Lii Cheng et al.

Summary: The study demonstrated that atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma patients led to improved survival outcomes. After updated analysis, atezolizumab plus bevacizumab maintained its position as the first-line treatment option for advanced hepatocellular carcinoma.

JOURNAL OF HEPATOLOGY (2022)

添加到收藏夹

Article Oncology

Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial

Yoon-Koo Kang et al.

Summary: This study investigated the efficacy of nivolumab plus oxaliplatin-based chemotherapy for HER2-negative, unresectable, advanced or recurrent gastric or gastro-oesophageal junction cancer, showing a significant improvement in progression-free survival but not overall survival in Asian patients. The combination therapy may potentially serve as a new first-line treatment option for these patients.

LANCET ONCOLOGY (2022)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial

Jason J. Luke et al.

Summary: The study demonstrates that Pembrolizumab as adjuvant therapy significantly prolongs recurrence-free survival in patients with stage II melanoma, with manageable safety profile.

LANCET (2022)

添加到收藏夹

Article Pharmacology & Pharmacy

Pancreatic Adverse Events Associated With Immune Checkpoint Inhibitors: A Large-Scale Pharmacovigilance Analysis

Yue Zhang et al.

Summary: This study examined the association between immune checkpoint inhibitors (ICIs) and pancreatic adverse events (AEs) using the FAERS database. It identified the main features of ICI-related pancreatic injury (ICIPI) and found that combination therapy has a stronger association with ICI-associated pancreatitis and ICI-associated diabetes mellitus.

FRONTIERS IN PHARMACOLOGY (2022)

添加到收藏夹

Article Oncology

Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312) : a multicentre, open-label, randomised, phase 3 trial

Robin Kate Kelley et al.

Summary: This study evaluated the combination of cabozantinib and atezolizumab versus sorafenib as first-line systemic treatment for advanced hepatocellular carcinoma. The combination treatment group showed better progression-free survival compared to the sorafenib group, but overall survival did not reach statistical significance. Common adverse events in the combination group included liver enzyme elevation, hypertension, and skin reactions. The study suggests that cabozantinib plus atezolizumab may be a treatment option, but further research is needed.

LANCET ONCOLOGY (2022)

添加到收藏夹

Article Medicine, General & Internal

Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial

Sumanta Kumar Pal et al.

Summary: The objective of this study was to determine if adjuvant atezolizumab delayed recurrence in renal cell carcinoma patients with an increased risk of recurrence. The study found that adjuvant atezolizumab did not improve clinical outcomes in patients with renal cell carcinoma.

LANCET (2022)

添加到收藏夹

Article Oncology

Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial

Mary O'Brien et al.

Summary: This study evaluated the use of Pembrolizumab as adjuvant therapy for completely resected stage IB-IIIA NSCLC. The results showed that Pembrolizumab significantly improved disease-free survival in both the overall population and the PD-L1 TPS of 50% or greater population.

LANCET ONCOLOGY (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial

Miranda Gogishvili et al.

Summary: First-line cemiplimab plus chemotherapy shows significant improvement in overall survival in advanced non-small cell lung cancer patients, regardless of PD-L1 expression or histology.

NATURE MEDICINE (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial

Solange Peters et al.

Summary: Selection of non-small cell lung cancer patients based on high blood-based tumor mutation burden did not improve clinical response, further research is needed.

NATURE MEDICINE (2022)

添加到收藏夹

Article Oncology

Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100

Markus Moehler et al.

Summary: The use of avelumab as maintenance therapy after first-line chemotherapy did not show superior overall survival compared to continued chemotherapy in patients with advanced GC or GEJC, regardless of PD-L1 status. Treatment-related adverse events occurred in both groups, with more severe events in the continued chemotherapy group.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial

Makoto Nishio et al.

Summary: The IMpower132 study demonstrated significant improvement in PFS with APP compared to PP, but the difference in OS between the two groups was not statistically significant. APP showed favorable OS and PFS results across subgroups, with a manageable safety profile and no new or unexpected safety signals identified.

JOURNAL OF THORACIC ONCOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial

Paul Baas et al.

Summary: Nivolumab plus ipilimumab demonstrated significant improvement in overall survival compared to standard chemotherapy for unresectable malignant pleural mesothelioma. This first-in-class treatment regimen has been approved for previously untreated patients in the USA and showed promising outcomes with manageable adverse events.

LANCET (2021)

添加到收藏夹

Article Oncology

Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

Jonathan W. Goldman et al.

Summary: The study showed that first-line treatment with durvalumab plus platinum-etoposide resulted in sustained improvement in overall survival, while the addition of tremelimumab to this combination did not significantly enhance efficacy. These findings support the use of durvalumab plus platinum-etoposide as a new standard of care for extensive-stage small-cell lung cancer.

LANCET ONCOLOGY (2021)

添加到收藏夹

Article Oncology

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

Luis Paz-Ares et al.

Summary: The combination of first-line nivolumab plus ipilimumab with a limited course of chemotherapy showed a significant improvement in overall survival for patients with advanced non-small-cell lung cancer, supporting it as a new treatment option for this patient population.

LANCET ONCOLOGY (2021)

添加到收藏夹

Review Mathematical & Computational Biology

Investigating and dealing with publication bias and other reporting biases in meta-analyses of health research: A review

Matthew J. Page et al.

Summary: Bias in meta-analysis may occur when available results differ systematically from missing results. Various tools, plots, and statistical methods have been designed to assess risk of bias due to missing results in meta-analyses of health research, including comparing prespecified analysis plans with completed reports to detect selective nonreporting of results and using funnel plots to identify small-study effects caused by reporting bias. Information from funnel plots and selection models may be more difficult to interpret compared to objective approaches like detecting incompletely reported results with available analysis plans.

RESEARCH SYNTHESIS METHODS (2021)

添加到收藏夹

Article Oncology

Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial

Dean A. Fennell et al.

Summary: The study evaluated the efficacy and safety of nivolumab in patients with pleural or peritoneal malignant mesothelioma who had progressed following platinum-based chemotherapy. Nivolumab showed improved progression-free survival and overall survival compared to placebo in these patients, with manageable treatment-related adverse events. The results suggest that nivolumab might be a beneficial treatment for patients with malignant mesothelioma who have progressed on first-line therapy.

LANCET ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial

Joaquim Bellmunt et al.

Summary: IMvigor010 is the largest adjuvant study evaluating a checkpoint inhibitor in muscle-invasive urothelial carcinoma. The trial did not show improved disease-free survival with atezolizumab compared to observation. Atezolizumab was generally well tolerated, but higher rates of adverse events leading to discontinuation were reported compared to previous studies on metastatic urothelial carcinoma.

LANCET ONCOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma

T. K. Choueiri et al.

Summary: The study demonstrates that nivolumab plus cabozantinib has significant advantages over sunitinib in the treatment of previously untreated advanced renal-cell carcinoma, including progression-free survival, overall survival, and likelihood of response.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Oncology

Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39)

Kathleen N. Moore et al.

Summary: The study evaluated the addition of the humanized monoclonal antiprogrammed death ligand-1 (PD-L1) antibody atezolizumab to platinum-based chemotherapy and bevacizumab in newly diagnosed stage III or IV ovarian cancer, showing a significant progression-free survival advantage in the PD-L1-positive population. However, no significant overall survival benefit was observed from atezolizumab in the interim analysis. The most common grade 3 or 4 adverse events were neutropenia, hypertension, and anemia.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

Nancy Y Lee et al.

LANCET ONCOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study

Jong-Mu Sun et al.

Summary: This study aimed to evaluate the antitumor activity of pembrolizumab plus chemotherapy versus chemotherapy alone as first-line treatment in advanced esophageal cancer. Results showed that pembrolizumab plus chemotherapy significantly improved overall survival and progression-free survival in patients with esophageal squamous cell carcinoma.

LANCET (2021)

添加到收藏夹

Article Medicine, General & Internal

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial

Yelena Y. Janjigian et al.

Summary: Nivolumab plus chemotherapy showed superior overall survival and progression-free survival compared to chemotherapy alone in previously untreated patients with advanced gastric, gastro-oesophageal junction, or oesophageal adenocarcinoma, indicating it as a new standard first-line treatment option with acceptable safety profile.

LANCET (2021)

添加到收藏夹

Article Medicine, General & Internal

Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial

Enriqueta Felip et al.

Summary: IMpower010 study demonstrated a disease-free survival benefit with adjuvant atezolizumab versus best supportive care in patients who underwent complete resection followed by adjuvant chemotherapy, especially in the subgroup whose tumors expressed PD-L1 on 1% or more of tumor cells.

LANCET (2021)

添加到收藏夹

Article Oncology

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Thomas Powles et al.

Summary: The study examined the outcomes of using pembrolizumab alone or combined with chemotherapy as first-line treatment for advanced urothelial carcinoma, and found that the addition of pembrolizumab to platinum-based chemotherapy did not significantly improve efficacy. Safety was assessed and the study concluded that this combination treatment should not be widely adopted for this type of cancer.

LANCET ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study

Eric Pujade-Lauraine et al.

Summary: This study compared the efficacy of avelumab alone, avelumab plus PLD, and PLD alone in patients with platinum-resistant or platinum-refractory ovarian cancer. The results showed that neither avelumab plus PLD nor avelumab alone significantly improved progression-free survival or overall survival compared to PLD.

LANCET ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study

Zhenggang Ren et al.

Summary: The study aimed to assess the efficacy of sintilimab plus IBI305 versus sorafenib as a first-line treatment for unresectable HBV-associated hepatocellular carcinoma in China, showing significant overall survival and progression-free survival benefits with acceptable safety profiles.

LANCET ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial

Bradley J. Monk et al.

Summary: The JAVELIN Ovarian 100 trial compared the efficacy of avelumab in combination with chemotherapy followed by avelumab maintenance, avelumab plus chemotherapy followed by avelumab maintenance, or chemotherapy alone in treatment-naive epithelial ovarian cancer patients. Results showed that avelumab did not demonstrate significant benefits in frontline treatment, suggesting the need for alternative treatment regimens to improve outcomes in advanced epithelial ovarian cancer patients.

LANCET ONCOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma

D. F. Bajorin et al.

Summary: In a trial involving patients with high-risk muscle-invasive urothelial carcinoma who had undergone radical surgery, adjuvant nivolumab showed longer disease-free survival compared to placebo, especially among patients with a PD-L1 expression level of 1% or more, despite an increase in treatment-related adverse events.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Oncology

Workup and Management of Immune-Mediated Hepatobiliary Pancreatic Toxicities That Develop During Immune Checkpoint Inhibitor Treatment

Christine Hsu et al.

ONCOLOGIST (2020)

添加到收藏夹

Article Oncology

ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer

D. Planchard et al.

ANNALS OF ONCOLOGY (2020)

添加到收藏夹

Review Oncology

Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer A Systematic Review and Meta-analysis

Jianchun Duan et al.

JAMA ONCOLOGY (2020)

添加到收藏夹

Letter Emergency Medicine

Population, Intervention, Comparison, Outcomes and Study (PICOS) design as a framework to formulate eligibility criteria in systematic reviews

Mehrdad Amir-Behghadami et al.

EMERGENCY MEDICINE JOURNAL (2020)

添加到收藏夹

Article Oncology

Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non-Small-Cell Lung Cancer

Martin Reck et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study

Charles M. Rudin et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Review Oncology

Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls

Eli P. Darnell et al.

CURRENT ONCOLOGY REPORTS (2020)

添加到收藏夹

Article Oncology

Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial

Robert Jotte et al.

JOURNAL OF THORACIC ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study

Jing Huang et al.

LANCET ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma The CheckMate 143 Phase 3 Randomized Clinical Trial

David A. Reardon et al.

JAMA ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer The MYSTIC Phase 3 Randomized Clinical Trial

Naiyer A. Rizvi et al.

JAMA ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11)

Yunpeng Yang et al.

JOURNAL OF THORACIC ONCOLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial

Ralf Gutzmer et al.

LANCET (2020)

添加到收藏夹

Article Medicine, General & Internal

Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial

Elizabeth A. Mittendorf et al.

LANCET (2020)

添加到收藏夹

Article Oncology

Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

Thomas Powles et al.

LANCET ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial

Thomas Powles et al.

LANCET ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial

Kohei Shitara et al.

JAMA ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial

Yi-Long Wu et al.

JOURNAL OF THORACIC ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury

Hamzah Abu-Sbeih et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)

添加到收藏夹

Letter Endocrinology & Metabolism

T-Lymphocyte Infiltration to Islets in the Pancreas of a Patient Who Developed Type 1 Diabetes After Administration of Immune Checkpoint Inhibitors

Sho Yoneda et al.

DIABETES CARE (2019)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony S. K. Mok et al.

LANCET (2019)

添加到收藏夹

Article Oncology

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

Howard West et al.

LANCET ONCOLOGY (2019)

添加到收藏夹

Review Gastroenterology & Hepatology

Incidence of pancreatitis with the use of immune checkpoint inhibitors (ICI) in advanced cancers: A systematic review and meta-analysis

John George et al.

PANCREATOLOGY (2019)

添加到收藏夹

Article Oncology

Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial

Cathy Eng et al.

LANCET ONCOLOGY (2019)

添加到收藏夹

Review Endocrinology & Metabolism

The multifaceted nature of diabetes mellitus induced by checkpoint inhibitors

Lucien Marchand et al.

ACTA DIABETOLOGICA (2019)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Barbara Burtness et al.

LANCET (2019)

添加到收藏夹

Article Oncology

Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater

Martin Reck et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

Ezra E. W. Cohen et al.

LANCET (2019)

添加到收藏夹

Article Oncology

Significance of Immune-related Lipase Increase Induced by Antiprogrammed Death-1 or Death Ligand-1 Antibodies: A Brief Communication

Jean-Marie Michot et al.

JOURNAL OF IMMUNOTHERAPY (2018)

添加到收藏夹

Review Gastroenterology & Hepatology

Autoimmune Pancreatitis

Sajan Jiv Singh Nagpal et al.

AMERICAN JOURNAL OF GASTROENTEROLOGY (2018)

添加到收藏夹

Article Oncology

Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial

James Larkin et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

Julie R. Brahmer et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

添加到收藏夹

Article Oncology

New NCCN Guidelines: Recognition and Management of Immunotherapy-Related Toxicity

John A. Thompson

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2018)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

Kohei Shitara et al.

LANCET (2018)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer

L. Gandhi et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Article Medicine, General & Internal

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

R. J. Motzer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Review Multidisciplinary Sciences

Cancer immunotherapy using checkpoint blockade

Antoni Ribas et al.

SCIENCE (2018)

添加到收藏夹

Review Immunology

Risk of Immune-Related Pancreatitis in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors: Systematic Assessment with Meta-Analysis

Qiang Su et al.

JOURNAL OF IMMUNOLOGY RESEARCH (2018)

添加到收藏夹

Article Oncology

Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300

Y. -J. Bang et al.

ANNALS OF ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer

Kathryn C. Arbour et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

添加到收藏夹

Review Biochemistry & Molecular Biology

Immune checkpoint inhibitors: recent progress and potential biomarkers

Pramod Darvin et al.

EXPERIMENTAL AND MOLECULAR MEDICINE (2018)

添加到收藏夹

Article Oncology

Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma

M. H. Pollack et al.

ANNALS OF ONCOLOGY (2018)

添加到收藏夹

Review Oncology

Comprehensive analysis of the clinical immuno-oncology landscape

J. Tang et al.

ANNALS OF ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Thinking Critically About Classifying Adverse Events: Incidence of Pancreatitis in Patients Treated With Nivolumab plus Ipilimumab

Claire F. Friedman et al.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)

添加到收藏夹

Article Oncology

Thinking Critically About Classifying Adverse Events: Incidence of Pancreatitis in Patients Treated With Nivolumab plus Ipilimumab

Claire F. Friedman et al.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)

添加到收藏夹

Article Medicine, General & Internal

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

J. D. Wolchok et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Article Pharmacology & Pharmacy

Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis

Peng-Fei Wang et al.

FRONTIERS IN PHARMACOLOGY (2017)

添加到收藏夹

Review Medical Laboratory Technology

Lipase or amylase for the diagnosis of acute pancreatitis?

Ola Z. Ismail et al.

CLINICAL BIOCHEMISTRY (2017)

添加到收藏夹

Article Oncology

Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy

Lars Hofmann et al.

EUROPEAN JOURNAL OF CANCER (2016)

添加到收藏夹

Article Oncology

Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer

Martin Reck et al.

JOURNAL OF CLINICAL ONCOLOGY (2016)

添加到收藏夹

Article Oncology

Immune-related pancreatitis secondary to nivolumab in a patient with recurrent lung adenocarcinoma: A case report

Kazuhiko Ikeuchi et al.

LUNG CANCER (2016)

添加到收藏夹

Article Medicine, Research & Experimental

Meta-analysis in clinical trials revisited

Rebecca DerSimonian et al.

CONTEMPORARY CLINICAL TRIALS (2015)

添加到收藏夹

Review Oncology

Immune Checkpoint Blockade in Cancer Therapy

Michael A. Postow et al.

JOURNAL OF CLINICAL ONCOLOGY (2015)

添加到收藏夹

Article Oncology

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

Jeffrey S. Weber et al.

LANCET ONCOLOGY (2015)

添加到收藏夹

Article Medicine, General & Internal

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

J. Larkin et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

添加到收藏夹

Article Oncology

Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab

Sree Harsha Tirumani et al.

CANCER IMMUNOLOGY RESEARCH (2015)

添加到收藏夹

Article Surgery

Roux-en-Y gastric bypass: hyperamylasemia is associated with small bowel obstruction

David Spector et al.

Surgery for Obesity and Related Diseases (2014)

添加到收藏夹

Article Oncology

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

Eugene D. Kwon et al.

LANCET ONCOLOGY (2014)

添加到收藏夹

Editorial Material Medicine, General & Internal

Relative risks versus odds ratios

Philip Sedgwick

BMJ-BRITISH MEDICAL JOURNAL (2014)

添加到收藏夹

Article Oncology

Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma

Antoni Ribas et al.

JOURNAL OF CLINICAL ONCOLOGY (2013)

添加到收藏夹

Article Oncology

Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab

Jeffrey S. Weber et al.

JOURNAL OF CLINICAL ONCOLOGY (2012)

添加到收藏夹

Article Medicine, General & Internal

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

Julian P. T. Higgins et al.

BMJ-BRITISH MEDICAL JOURNAL (2011)

添加到收藏夹

Article Medicine, General & Internal

Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials

Jonathan A. C. Sterne et al.

BMJ-BRITISH MEDICAL JOURNAL (2011)

添加到收藏夹

Article Computer Science, Interdisciplinary Applications

Conducting Meta-Analyses in R with the metafor Package

Wolfgang Viechtbauer

JOURNAL OF STATISTICAL SOFTWARE (2010)

添加到收藏夹

Article Gastroenterology & Hepatology

The Role of Etiology in the Hyperamylasemia of Acute Liver Failure

Gregory A. Cote et al.

AMERICAN JOURNAL OF GASTROENTEROLOGY (2009)

添加到收藏夹

Review Medicine, General & Internal

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

David Moher et al.

PLOS MEDICINE (2009)

添加到收藏夹

Article Mathematical & Computational Biology

A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints

Roger M. Harbord et al.

STATISTICS IN MEDICINE (2006)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.